<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00140309</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCHSTP-3716</org_study_id>
    <nct_id>NCT00140309</nct_id>
  </id_info>
  <brief_title>TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment</brief_title>
  <official_title>TBTC Study 27: An Evaluation of the Activity and Tolerability of Moxifloxacin During the First Two Months of Treatment for Pulmonary Tuberculosis--A Double-Blind, Randomized, Multicenter Study by the Tuberculosis Trials Consortium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a placebo-controlled factorial study, randomized to study drug (moxifloxacin&#xD;
      vs. ethambutol) and treatment frequency (daily vs. thrice weekly after an initial two weeks&#xD;
      of daily therapy) during the first two months of standard treatment (with isoniazid,&#xD;
      rifampin, and pyrazinamide) for sputum smear-positive pulmonary tuberculosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this Phase II clinical trial is to compare the safety and&#xD;
      microbiological activity of a moxifloxacin-containing regimen (isoniazid, rifampin,&#xD;
      pyrazinamide, moxifloxacin [HRZMoxi]) to a control regimen (isoniazid, rifampin,&#xD;
      pyrazinamide, ethambutol [HRZE]) in the first two months of treatment of sputum&#xD;
      smear-positive pulmonary tuberculosis. In addition, the study will evaluate whether&#xD;
      intermittent administration (thrice-weekly after the first 2 weeks) of these regimens affects&#xD;
      their tolerability and microbiological activity. The assessment of microbiological activity&#xD;
      will be sputum culture-conversion. Improved sputum culture conversion after 2 months of&#xD;
      treatment with a moxifloxacin-containing regimen would support phase 3 clinical trials of&#xD;
      moxifloxacin in treatment regimens of less than the current 6 month standard regimens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Two-month culture conversion</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Event</measure>
  </primary_outcome>
  <enrollment>350</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin (with isoniazid, rifampin, pyrazinamide)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Suspected pulmonary tuberculosis with acid-fast bacilli in a stained sputum smear -&#xD;
             patients whose sputum cultures do not grow M. tuberculosis and those having an M.&#xD;
             tuberculosis isolate resistant to rifampin will be discontinued from the study, but&#xD;
             followed for 14 days to detect late toxicities from study therapy. Patients having&#xD;
             extra-pulmonary manifestations of tuberculosis, in addition to smear-positive&#xD;
             pulmonary disease, are eligible for enrollment.&#xD;
&#xD;
          2. Willingness to have HIV testing performed, if HIV serostatus is not known or if the&#xD;
             last documented negative HIV test was more than 6 months prior to enrollment&#xD;
&#xD;
          3. 7 or fewer days of tuberculosis therapy in the 6 months preceding enrollment&#xD;
&#xD;
          4. Age &gt; 18 years&#xD;
&#xD;
          5. Karnofsky score of at least 60&#xD;
&#xD;
          6. Signed informed consent&#xD;
&#xD;
          7. Women with child-bearing potential must agree to practice an adequate (barrier) method&#xD;
             of birth control or to abstain from heterosexual sex.&#xD;
&#xD;
          8. Laboratory parameters within 14 days of enrollment:&#xD;
&#xD;
               -  Serum amino aspartate transferase (AST) activity less than 3 times the upper&#xD;
                  limit of normal&#xD;
&#xD;
               -  Serum total bilirubin level less than 2.5 times upper limit of normal&#xD;
&#xD;
               -  Serum creatinine level less than 2 times upper limit of normal&#xD;
&#xD;
               -  Hemoglobin level of at least 7.0 g/dL&#xD;
&#xD;
               -  Platelet count of at least 50,000/mm3&#xD;
&#xD;
               -  Serum potassium &gt; 3.0 meq/L&#xD;
&#xD;
               -  Negative pregnancy test (for women of childbearing potential)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Breast-feeding&#xD;
&#xD;
          2. Known intolerance to any of the study drugs&#xD;
&#xD;
          3. Known allergy to any fluoroquinolone antibiotic&#xD;
&#xD;
          4. Current or planned therapy during the first 2 months of tuberculosis treatment using&#xD;
             drugs having unacceptable interactions with rifampin (rifabutin can be substituted for&#xD;
             rifampin during the continuation phase of therapy)&#xD;
&#xD;
          5. Current or planned antiretroviral therapy during the first 2 months of tuberculosis&#xD;
             treatment&#xD;
&#xD;
          6. History of prolonged QT syndrome or current or planned therapy with quinidine,&#xD;
             procainamide, amiodarone, sotalol, or ziprasidone during the first 2 months of&#xD;
             tuberculosis treatment.&#xD;
&#xD;
          7. Pulmonary silicosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Burman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Public Health Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard E Chaisson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Public Health Department</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington DC Veterans Administration Medical Center</name>
      <address>
        <city>Washington DC</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hines Vetrans Administration Medical Center</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey School of Medicine</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Tennessee Valley Health Care System</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Texas Health Science Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Veterans Administration Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Audie L Murphy Memorial Veterans Administration Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle-King County Health Department</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nelson R Mandela School of Medicine</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makerere University Medical School</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>South Africa</country>
    <country>Uganda</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cdc.gov/nchstp/tb/tbtc/default.htm</url>
    <description>Tuberculosis Trials Consortium (TBTC) web page</description>
  </link>
  <results_reference>
    <citation>Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006 Aug 1;174(3):331-8. Epub 2006 May 4.</citation>
    <PMID>16675781</PMID>
  </results_reference>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <last_update_submitted>March 16, 2007</last_update_submitted>
  <last_update_submitted_qc>March 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2007</last_update_posted>
  <keyword>TB</keyword>
  <keyword>Pulmonary Tuberculosis</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Pulmonary TB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

